Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
Hundreds of lawsuits allege that GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, may increase the risk of NAION, a rare form of vision loss. Novo Nordisk and Eli Lilly dispute these claims, citing research showing no increased risk. Studies have shown a modest increase in NAION risk with semaglutide, but the FDA has not issued a safety warning.
How this was made
The 30-second read
Why it matters
It highlights ongoing FDA evidence review for semaglutide and an EMA decision to add NAION as a very rare adverse reaction, while companies dispute causality and continue monitoring.
Market read
Active litigation plus regulator review keeps GLP-1 safety risk in focus, which can drive near-term volatility and valuation sensitivity to any label or warning changes.
What to watch
The article notes major NAION risk factors (age, diabetes, hypertension, sleep apnea) that may confound observational results; also, semaglutide-focused evidence may not translate 1:1 to tirzepatide products.
Background
The article frames NAION as an “eye stroke” with sudden, often permanent vision loss and describes observational studies linking semaglutide to modestly higher relative risk.
Ticker impact
Lawsuits allege Novo Nordisk’s Ozempic and Wegovy increase NAION risk, while the company disputes the claims and cites research.
Near-term downside bias on any escalation in FDA review, additional adverse findings, or settlement headlines; longer-term depends on whether regulators add stronger warnings.
The article ties NVO to active litigation plus ongoing FDA evidence review and an EMA label update, which can drive risk repricing even without a concluded causal finding.
Eli Lilly’s Mounjaro and Zepbound are named in NAION-related lawsuits, with Lilly monitoring safety data and saying studies do not prove causation.
Potential volatility around regulatory/litigation updates; likely limited fundamental damage unless evidence shifts toward causality or stronger warnings.
The piece reports disputed allegations, observational-study signals for semaglutide, and regulator actions (FDA review, EMA label change) that can spill over to the broader class narrative.
Market effects
Reinforces a class-level safety narrative for GLP-1 receptor agonists, potentially affecting valuation multiples and demand expectations across the obesity/diabetes drug complex.
Could influence European sentiment more immediately given EMA’s recommendation to add NAION as a very rare adverse reaction.
May affect global GLP-1 regulatory and litigation risk pricing, especially if FDA moves toward a warning or label update.
Counterpoint
Because NAION is rare and studies are observational, the market may overreact to litigation headlines; if FDA does not change labeling, the incremental risk premium could fade.
Key entities
- companyNovo Nordisk
Maker of Ozempic and Wegovy, named in NAION lawsuits and disputing the allegations with company-funded research.
- companyEli Lilly
Maker of Mounjaro and Zepbound, named in NAION lawsuits and stating current studies do not prove causation.
- regulatorFDA
Said to be reviewing available evidence on a possible semaglutide-NAION association, without issuing a safety warning yet.
- regulatorEuropean Medicines Agency
Recommended adding NAION as a very rare adverse reaction to semaglutide product information in Europe.
